CSL Limited (OTCMKTS:CSLLY – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as $75.70 and last traded at $79.07, with a volume of 116648 shares changing hands. The stock had previously closed at $78.95.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group upgraded CSL to a “strong-buy” rating in a research report on Thursday, January 16th.
Check Out Our Latest Stock Analysis on CSL
CSL Stock Performance
CSL Company Profile
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
- Five stocks we like better than CSL
- Conference Calls and Individual Investors
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- What Are the FAANG Stocks and Are They Good Investments?
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Differences Between Momentum Investing and Long Term Investing
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
